NASDAQ:CYCC - Cyclacel Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.45 +0.03 (+2.11 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$1.45
Today's Range$1.42 - $1.4632
52-Week Range$1.28 - $4.94
Volume11,178 shs
Average Volume162,284 shs
Market Capitalization$17.16 million
P/E RatioN/A
Dividend YieldN/A
Beta3.64

About Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Cyclacel Pharmaceuticals logoCyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Receive CYCC News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYCC
CUSIPN/A
Phone908-517-7330

Debt

Debt-to-Equity RatioN/A
Current Ratio5.82
Quick Ratio5.82

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$840,000.00
Price / Sales20.71
Cash FlowN/A
Price / CashN/A
Book Value$1.70 per share
Price / Book0.85

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-7,470,000.00
Net MarginsN/A
Return on Equity-37.72%
Return on Assets-30.76%

Miscellaneous

Employees12
Outstanding Shares12,000,000

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Cyclacel Pharmaceuticals's stock reverse split on Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) posted its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. View Cyclacel Pharmaceuticals' Earnings History.

Who are some of Cyclacel Pharmaceuticals' key competitors?

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the folowing people:
  • Mr. Spiro George Rombotis, CEO, Pres & Exec. Director (Age 59)
  • Mr. Paul McBarron, CFO, COO, Exec. VP of Fin., Sec. & Exec. Director (Age 57)
  • Dr. Judy H. Chiao M.D., VP of Clinical Devel. & Regulatory Affairs (Age 58)
  • Prof. David Glover Ph.D., FRS FRSE, Chief Scientist (Age 70)
  • Ms. Gill Christie, Director of HR (Age 61)

Has Cyclacel Pharmaceuticals been receiving favorable news coverage?

News stories about CYCC stock have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a news sentiment score of 0.21 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 47.67 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $1.45.

How big of a company is Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals has a market capitalization of $17.16 million and generates $840,000.00 in revenue each year. Cyclacel Pharmaceuticals employs 12 workers across the globe.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]


MarketBeat Community Rating for Cyclacel Pharmaceuticals (CYCC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  75 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  150
MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote "Outperform" if you believe CYCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Cyclacel Pharmaceuticals in the last 12 months. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 3.003.00N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Consensus Price Target History

Price Target History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018HC WainwrightReiterated RatingBuyHighView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Earnings History and Estimates Chart

Earnings by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.43 EPS
Next Year EPS Consensus Estimate: $-0.37 EPS

Cyclacel Pharmaceuticals (NASDAQ CYCC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018Q1 2018($0.13)($0.1170)ViewListenView Earnings Details
11/9/2017Q3 2017($0.91)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.50)ViewListenView Earnings Details
5/11/2017Q1 2017($0.38)ViewN/AView Earnings Details
3/28/2017Q4 2016($0.73)($0.69)$0.21 million$0.28 millionViewN/AView Earnings Details
11/14/2016Q316($0.94)($0.86)$0.42 million$0.21 millionViewN/AView Earnings Details
8/10/2016Q216($1.01)$0.22 millionViewListenView Earnings Details
5/11/2016Q116($0.09)$512.00 million$139.00 millionViewListenView Earnings Details
3/24/2016Q4($0.08)($0.10)$0.51 million$0.42 millionViewListenView Earnings Details
11/12/2015Q315($0.09)($0.08)$0.30 million$0.72 millionViewListenView Earnings Details
8/11/2015Q215($0.10)$0.30 millionViewListenView Earnings Details
5/12/2015Q115($0.25)($0.19)$0.51 millionViewListenView Earnings Details
3/24/2015Q414($0.26)($0.21)$0.25 millionViewN/AView Earnings Details
11/11/2014Q314($0.26)($0.22)$0.74 millionViewN/AView Earnings Details
8/12/2014Q214($0.28)($0.22)$0.36 millionViewN/AView Earnings Details
5/13/2014Q114($0.24)($0.25)$0.40 millionViewN/AView Earnings Details
3/25/2014Q413($0.33)($0.19)$0.09 million$0.2990 millionViewN/AView Earnings Details
11/12/2013Q3($0.31)($0.31)$0.31 millionViewListenView Earnings Details
8/14/2013Q2 2013($0.10)$0.0260 million$0.2640 millionViewN/AView Earnings Details
5/13/2013Q1 2013($1.18)$0.21 millionViewN/AView Earnings Details
3/27/2013Q4 2012($6.60)ViewN/AView Earnings Details
11/12/2012Q312($0.37)ViewN/AView Earnings Details
8/14/2012Q2 2012($6.72)($5.04)ViewN/AView Earnings Details
5/14/2012Q1 2012($6.72)($5.04)ViewN/AView Earnings Details
3/29/2012Q4 2011($6.72)($5.96)ViewN/AView Earnings Details
11/14/2011Q3 2011($6.72)($5.71)ViewN/AView Earnings Details
8/11/2011Q2 2011($9.24)($6.72)ViewN/AView Earnings Details
5/12/2011Q1 2011($7.56)($8.57)ViewN/AView Earnings Details
3/23/2011Q4 2010($8.40)($6.13)ViewN/AView Earnings Details
11/11/2010Q3 2010($12.60)($9.07)ViewN/AView Earnings Details
8/5/2010Q2 2010($14.28)($15.04)ViewN/AView Earnings Details
5/13/2010Q1 2010($12.60)($15.37)ViewN/AView Earnings Details
3/23/2010Q4 2009($14.28)($14.79)ViewN/AView Earnings Details
11/3/2009Q3 2009($18.48)($10.92)ViewN/AView Earnings Details
8/6/2009Q2 2009($21.84)($20.50)ViewN/AView Earnings Details
5/14/2009Q1 2009($25.20)($20.83)ViewN/AView Earnings Details
3/31/2009Q4 2008($27.72)($32.68)ViewN/AView Earnings Details
11/6/2008Q3 2008($36.12)($24.87)ViewN/AView Earnings Details
8/7/2008Q2 2008($31.92)($35.12)ViewN/AView Earnings Details
5/9/2008Q1 2008($32.76)($25.71)ViewN/AView Earnings Details
3/11/2008Q4 2007($34.44)($46.71)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/9/2016Annual$0.157/13/20167/17/20168/1/2016
(Data available from 1/1/2013 forward)

Insider Trades

Cyclacel Pharmaceuticals (NASDAQ CYCC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.46%
Institutional Ownership Percentage: 4.68%
Insider Trading History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Institutional Ownership by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Cyclacel Pharmaceuticals (NASDAQ CYCC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/19/2017Eastern Capital LtdMajor ShareholderBuy850,000$2.00$1,700,000.002,167,261View SEC Filing  
2/23/2017Kevin C TangMajor ShareholderBuy134,200$4.34$582,428.00View SEC Filing  
11/20/2014Sam L BarkerDirectorBuy3,100$3.00$9,300.00View SEC Filing  
5/21/2013Lloyd SemsDirectorBuy33,333$3.00$99,999.00View SEC Filing  
5/21/2013Paul McbarronCFOBuy12,948$3.03$39,232.44View SEC Filing  
5/21/2013Spiro George RombotisInsiderBuy100,000$3.00$300,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cyclacel Pharmaceuticals (NASDAQ CYCC) News Headlines

Source:
DateHeadline
Edited Transcript of CYCC earnings conference call or presentation 14-May-18 8:30pm GMTEdited Transcript of CYCC earnings conference call or presentation 14-May-18 8:30pm GMT
finance.yahoo.com - May 21 at 8:38 AM
Cyclacel Pharmaceuticals (CYCC) CEO Spiro Rombotis on Q1 2018 Results - Earnings Call TranscriptCyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 9:01 AM
Cyclacel (CYCC) Posts  Earnings Results, Beats Estimates By $0.01 EPSCyclacel (CYCC) Posts Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 15 at 8:28 AM
Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial ResultsCyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 14 at 5:03 PM
Cyclacel (CYCC) to Release Earnings on MondayCyclacel (CYCC) to Release Earnings on Monday
www.americanbankingnews.com - May 12 at 8:14 PM
-$0.13 Earnings Per Share Expected for Cyclacel (CYCC) This Quarter-$0.13 Earnings Per Share Expected for Cyclacel (CYCC) This Quarter
www.americanbankingnews.com - May 11 at 5:16 AM
Cyclacel (CYCC) Upgraded to "Hold" at ValuEngineCyclacel (CYCC) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - May 3 at 7:56 PM
Cyclacel (CYCC) versus Its Competitors Head to Head SurveyCyclacel (CYCC) versus Its Competitors Head to Head Survey
www.americanbankingnews.com - April 30 at 9:25 AM
Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual MeetingCyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting
feeds.benzinga.com - April 16 at 7:46 AM
Wired News – Stemline Therapeutics Initiates Rolling BLA Submission for SL-401Wired News – Stemline Therapeutics Initiates Rolling BLA Submission for SL-401
finance.yahoo.com - April 9 at 8:54 AM
-$0.13 EPS Expected for Cyclacel (CYCC) This Quarter-$0.13 EPS Expected for Cyclacel (CYCC) This Quarter
www.americanbankingnews.com - April 6 at 11:24 PM
Zacks Investment Research Lowers Cyclacel (CYCC) to HoldZacks Investment Research Lowers Cyclacel (CYCC) to Hold
www.americanbankingnews.com - April 6 at 9:50 PM
Cyclacel (CYCC) Upgraded at Zacks Investment ResearchCyclacel (CYCC) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 5 at 9:36 PM
Cyclacel (CYCC) Receives Buy Rating from HC WainwrightCyclacel (CYCC) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - April 3 at 7:48 AM
Edited Transcript of CYCC earnings conference call or presentation 28-Mar-18 8:30pm GMTEdited Transcript of CYCC earnings conference call or presentation 28-Mar-18 8:30pm GMT
finance.yahoo.com - March 29 at 8:55 AM
Cyclacel Pharmaceuticals, Inc. to Host Earnings CallCyclacel Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - March 28 at 5:00 PM
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial ResultsCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 28 at 5:00 PM
Cyclacel Pharmaceuticals (CYCC) Upgraded at ValuEngineCyclacel Pharmaceuticals (CYCC) Upgraded at ValuEngine
www.americanbankingnews.com - March 25 at 6:58 PM
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial ResultsCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 21 at 9:36 AM
Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual MeetingPhase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting
finance.yahoo.com - March 15 at 8:41 AM
Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH ConferenceCyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 14 at 9:16 AM
Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical FormulationsCyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations
finance.yahoo.com - March 1 at 8:35 AM
Cyclacel Pharma (CYCC) Announces New European Patent Covering Sapacitabine Pharmaceutical FormulationsCyclacel Pharma (CYCC) Announces New European Patent Covering Sapacitabine Pharmaceutical Formulations
www.streetinsider.com - February 21 at 8:47 AM
Cyclacel Pharmaceuticals (CYCC) Presents At BIO CEO & Investor Conference - SlideshowCyclacel Pharmaceuticals (CYCC) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 3:59 PM
Cyclacel Pharmaceuticals (CYCC) Presents At Noble Financial Capital Markets 14th Annual Investor Conference - SlideshowCyclacel Pharmaceuticals (CYCC) Presents At Noble Financial Capital Markets 14th Annual Investor Conference - Slideshow
seekingalpha.com - February 11 at 4:17 PM
Should You Be Concerned About Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Shareholders?Should You Be Concerned About Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Shareholders?
finance.yahoo.com - February 6 at 9:34 AM
Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor ConferenceCyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference
feeds.benzinga.com - February 6 at 7:43 AM
Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Earnings Declined -24.93%, But How Did It Fare Against The Industry?Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Earnings Declined -24.93%, But How Did It Fare Against The Industry?
finance.yahoo.com - January 20 at 9:53 AM
Cyclacel Pharma (CYCC) Reviews 2017 Achievements, Announces Key Business Objectives for 2018 - StreetInsider.comCyclacel Pharma (CYCC) Reviews 2017 Achievements, Announces Key Business Objectives for 2018 - StreetInsider.com
www.streetinsider.com - January 9 at 9:47 AM
Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018
finance.yahoo.com - January 9 at 9:47 AM
What You Must Know About Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Financial HealthWhat You Must Know About Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Financial Health
finance.yahoo.com - January 2 at 6:06 PM
Cyclacel (CYCC) Announces Presentation of Results From Phase 3 Seamless Study at ASHCyclacel (CYCC) Announces Presentation of Results From Phase 3 Seamless Study at ASH
www.streetinsider.com - December 13 at 5:12 PM
ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : December 13, 2017ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 5:12 PM
Cyclacel (CYCC) Announces Presentation of Results From Phase 3 Seamless Study at ASH - StreetInsider.comCyclacel (CYCC) Announces Presentation of Results From Phase 3 Seamless Study at ASH - StreetInsider.com
www.streetinsider.com - December 12 at 10:15 AM
Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual MeetingCyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting
finance.yahoo.com - December 12 at 10:15 AM
ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : November 27, 2017ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 6:06 PM
Cyclacel Pharmaceuticals (CYCC) CEO Spiro Rombotis on Q3 ... - Seeking AlphaCyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 ... - Seeking Alpha
seekingalpha.com - November 10 at 8:41 AM
Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial ResultsCyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 10 at 8:41 AM
Edited Transcript of CYCC earnings conference call or presentation 9-Nov-17 9:30pm GMTEdited Transcript of CYCC earnings conference call or presentation 9-Nov-17 9:30pm GMT
finance.yahoo.com - November 10 at 8:41 AM
Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results - GlobeNewswire (press release)Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 4 at 7:48 PM
Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial ResultsCyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results
feeds.benzinga.com - November 2 at 7:43 AM
Cyclacel Pharmaceuticals (CYCC) Presents At Ladenburg Thalmann 2017 Healthcare Conference - SlideshowCyclacel Pharmaceuticals (CYCC) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 6:49 PM
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference - GlobeNewswire (press release)Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 21 at 5:45 PM
Cyclacel Pharmaceuticals Preferred Stock Shares Cross 10% Yield MarkCyclacel Pharmaceuticals' Preferred Stock Shares Cross 10% Yield Mark
www.thestreet.com - September 19 at 5:44 PM
Short Interest in Cyclacel Pharmaceuticals, Inc. (CYCC) Decreases By 35.8%Short Interest in Cyclacel Pharmaceuticals, Inc. (CYCC) Decreases By 35.8%
www.americanbankingnews.com - September 17 at 1:20 AM
Todays Research Reports on Trending Tickers: Cyclacel Pharmaceuticals and MannKind CorporationToday's Research Reports on Trending Tickers: Cyclacel Pharmaceuticals and MannKind Corporation
finance.yahoo.com - September 13 at 7:01 PM
Cyclacel Pharmaceuticals (CYCC) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowCyclacel Pharmaceuticals (CYCC) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 12 at 6:24 PM
Short Interest in Cyclacel Pharmaceuticals, Inc. (CYCC) Drops By 23.5%Short Interest in Cyclacel Pharmaceuticals, Inc. (CYCC) Drops By 23.5%
www.americanbankingnews.com - August 14 at 2:38 AM
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Issues Quarterly  Earnings ResultsCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 10 at 11:04 PM
Edited Transcript of CYCC earnings conference call or presentation 9-Aug-17 8:30pm GMTEdited Transcript of CYCC earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 6:58 PM

SEC Filings

Cyclacel Pharmaceuticals (NASDAQ:CYCC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cyclacel Pharmaceuticals (NASDAQ CYCC) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.